CymaBay Therapeutics announces early enrollment of a phase 2b study of seladelpar
CymaBay announced early completion of enrollment in a Phase 2b dose-ranging, paired liver biopsy study of seladelpar for treatment of nonalcoholic steatohepatitis. The company expects to report 12-week topline results on changes in liver fat and key biochemical parameters in the second quarter. February 19, 2019